Body Mind StateFunding
Companies, investments, and funding rounds shaping neurotechnology and nervous-system health.
Recommended starting point
Editorially reviewed
The Series D adds capital for clinical and regulatory work. It does not turn Precision’s investigational brain–computer interface into an FDA-cleared permanent system.
Read this story1–3 of 3 stories
Funding
Editorially reviewed
The Series D adds capital for clinical and regulatory work. It does not turn Precision’s investigational brain–computer interface into an FDA-cleared permanent system.
$250 million · Series D
Funding
Editorially reviewed
The company announced financing to expand its eye-movement measurement platform. What the round establishes—and what still requires clinical evidence.
€10 million · Series A
Neurotech
Corrected
A sourced record of the company’s February 6, 2024 seed announcement. This was not a Series B announcement.
$12 million · seed
From the publication
Reviewed reporting, useful distinctions, and important corrections—in your inbox.
